Jul 5, 2024, 02:27
ESMO – Ipilimumab and nivolumab in unresected advanced Hepatocellular Carcinoma
ESMO shared on X:
“Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced Hepatocellular Carcinoma.
Read the opinion piece by Angela Lamarca on ESMO Daily Reporter.”
Read further.
Source: ESMO/X